Axon Enterprise, Inc $AXON Position Raised by Accuvest Global Advisors

Key Points

• Accuvest Global Advisors increased its Axon position by 595.3% in the third quarter, adding 6,834 shares to own 7,982 shares valued at about $3.37 million.
• Axon’s quarterly revenue rose 27.8% year over year to $908.55 million, but both revenue and EPS of $1.72 missed analyst expectations.
• Company insiders sold 37,397 shares worth about $21.2 million over the past three months. Following the results, some analysts cut price targets, and Craig Hallum downgraded the stock to Hold.

Accuvest Global Advisors grew its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 595.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,982 shares of the biotechnology company's stock after acquiring an additional 6,834 shares during the quarter. Axon Enterprise comprises about 2.5% of Accuvest Global Advisors' investment portfolio, making the stock its 12th largest holding. Accuvest Global Advisors' holdings in Axon Enterprise were worth $3,373,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Keel Point LLC boosted its position in shares of Axon Enterprise by 4.4% during the first quarter. Keel Point LLC now owns 599 shares of the biotechnology company's stock worth $254,000 after buying an additional 25 shares during the period. Bridgewater Advisors Inc. increased its position in Axon Enterprise by 4.4% in the 2nd quarter. Bridgewater Advisors Inc. now owns 616 shares of the biotechnology company's stock valued at $352,000 after acquiring an additional 26 shares during the period. Pinnacle Wealth Planning Services Inc. raised its stake in Axon Enterprise by 7.8% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 361 shares of the biotechnology company's stock valued at $153,000 after acquiring an additional 26 shares in the last quarter. 44 Wealth Management LLC raised its stake in Axon Enterprise by 6.0% during the 1st quarter. 44 Wealth Management LLC now owns 530 shares of the biotechnology company's stock valued at $225,000 after acquiring an additional 30 shares in the last quarter. Finally, Owl Creek Wealth Partners LLC boosted its position in Axon Enterprise by 84.8% during the 2nd quarter. Owl Creek Wealth Partners LLC now owns 85 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 39 shares during the period. Institutional investors own 79.08% of the company's stock.

Insider Transactions at Axon Enterprise

In related news, President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the transaction, the president directly owned 296,974 shares of the company's stock, valued at $170,590,774.82. The trade was a 5.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total transaction of $5,089,900.00. Following the completion of the sale, the chief executive officer owned 3,118,012 shares in the company, valued at approximately $1,587,036,927.88. This trade represents a 0.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 37,397 shares of company stock worth $21,234,034. Corporate insiders own 4.20% of the company's stock.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $313.00 on Monday. The stock has a market cap of $25.43 billion, a price-to-earnings ratio of 100.32, a PEG ratio of 5.95 and a beta of 1.48. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.00 and a quick ratio of 2.60. Axon Enterprise, Inc has a 12 month low of $307.00 and a 12 month high of $665.07. The stock's 50 day moving average price is $441.53 and its 200 day moving average price is $475.20.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.89 by ($0.17). Axon Enterprise had a net margin of 7.56% and a return on equity of 3.87%. The firm had revenue of $908.55 million for the quarter, compared to the consensus estimate of $934.33 million. During the same period in the previous year, the business posted $1.17 earnings per share. The business's revenue for the quarter was up 27.8% compared to the same quarter last year. Equities research analysts anticipate that Axon Enterprise, Inc will post 2.10 earnings per share for the current fiscal year.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Analyst Upgrades and Downgrades

AXON has been the subject of several recent analyst reports. Argus increased their price target on Axon Enterprise from $460.00 to $600.00 and gave the stock a "buy" rating in a research note on Thursday, September 3rd. Needham & Company LLC cut their price objective on shares of Axon Enterprise from $750.00 to $500.00 and set a "buy" rating on the stock in a research note on Friday. Royal Bank Of Canada cut their price objective on shares of Axon Enterprise from $735.00 to $615.00 and set an "outperform" rating on the stock in a research note on Friday. Craig Hallum downgraded shares of Axon Enterprise from a "buy" rating to a "hold" rating and set a $390.00 price objective for the company. in a report on Friday. Finally, Raymond James Financial set a $675.00 target price on shares of Axon Enterprise in a research report on Thursday, October 15th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $631.35.

Axon Enterprise Company Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.